BIOPHARM FORWARD ApS Financials, key figures and credit report
Gross profit 997.2 kDKK FY 2025 -5.6% vs 2024
EBIT 271.8 kDKK FY 2025 -18% vs 2024
Net debt -1 792.5 kDKK FY 2025 -12.3% vs 2024
Quick ratio 5.2 FY 2025 -0.8 vs 2024
Income statement (kDKK)
2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|
| Fiscal period length | 12 | 12 | 12 | 12 | 12 |
| Net sales | |||||
| Gross profit | 928.01 | 584.10 | 549.85 | 1 056.75 | 997.23 |
| Employee benefit expenses | - 253.72 | - 305.87 | - 679.49 | - 725.43 | - 725.47 |
| EBIT | 674.28 | 278.23 | - 129.64 | 331.32 | 271.76 |
| Other financial income | 1 075.60 | 70.66 | 35.68 | 171.67 | 50.45 |
| Other financial expenses | -9.89 | - 148.62 | -43.54 | -9.44 | -9.85 |
| Pre-tax profit | 1 739.99 | 200.28 | - 137.50 | 493.56 | 312.37 |
| Income taxes | - 283.14 | -44.15 | 30.20 | - 108.49 | -68.71 |
| Net earnings | 1 456.85 | 156.13 | - 107.30 | 385.06 | 243.66 |
Assets (kDKK)
2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|
| Intangible assets total | |||||
| Tangible assets total | |||||
| Investments total | |||||
| Long term receivables total | |||||
| Inventories total | |||||
| Current trade debtors | 128.13 | 120.63 | |||
| Current other receivables | 3.18 | ||||
| Current deferred tax assets | 116.86 | 188.09 | 134.90 | 87.48 | 75.41 |
| Short term receivables total | 116.86 | 191.27 | 134.90 | 215.60 | 196.04 |
| Other current investments | 1 080.46 | 993.64 | 978.97 | 1 150.09 | 179.40 |
| Cash and bank deposits | 591.07 | 643.82 | 587.86 | 691.94 | 1 869.09 |
| Cash and cash equivalents | 1 671.54 | 1 637.46 | 1 566.84 | 1 842.03 | 2 048.49 |
| Balance sheet total (assets) | 1 788.40 | 1 828.73 | 1 701.74 | 2 057.63 | 2 244.52 |
Equity and liabilities (kDKK)
2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|
| Share capital | 131.25 | 131.25 | 131.25 | 131.25 | 131.25 |
| Shares repurchased | 114.40 | 117.80 | 122.00 | 135.00 | 158.80 |
| Retained earnings | - 149.53 | 1 189.52 | 1 223.64 | 981.34 | 1 207.61 |
| Profit of the financial year | 1 456.85 | 156.13 | - 107.30 | 385.06 | 243.66 |
| Shareholders equity total | 1 552.97 | 1 594.69 | 1 369.59 | 1 632.65 | 1 741.32 |
| Non-current deferred tax liabilities | 78.30 | 68.71 | |||
| Non-current liabilities total | 78.30 | 68.71 | |||
| Current trade creditors | 6.60 | 6.60 | 25.66 | 6.60 | 6.60 |
| Current owed to participating | 218.14 | 226.87 | 235.94 | 245.38 | 256.00 |
| Short-term deferred tax liabilities | 78.30 | ||||
| Other non-interest bearing current liabilities | 10.69 | 0.57 | 70.54 | 94.70 | 93.60 |
| Current liabilities total | 235.43 | 234.04 | 332.15 | 346.68 | 434.50 |
| Balance sheet total (liabilities) | 1 788.40 | 1 828.73 | 1 701.74 | 2 057.63 | 2 244.52 |
Secure checkout
Buy AI Credit Risk Report
Pay by card and the report is generated automatically and sent to your email. One-time payment – no subscription.
How it works
- 01 You pay €3 (incl. VAT) securely by card via Stripe.
- 02 You enter your email address in Stripe's payment window – the report is sent there.
- 03 The report is generated automatically and sent as a PDF within 30 minutes.
- 04 If generation should fail, you are not charged.
- 05 You receive the receipt by email once the report has been generated and completed.
Do you want to buy the AI Credit Risk Report (3 EUR / report)?
The report is sent to the email address you enter in Stripe's payment window. Please also check your spam folder. Questions? Write to info@creditreports.dk.
Page generated